Effect of nitroxyl on human platelets function

Summary

There is a growing body of evidence on the role of nitric oxide (NO) in human platelet physiology regulation. Recently, interest has developed in the functional role of an alternative redox form of NO, namely nitroxyl (HNO/NO-), because it is formed by a number of diverse biochemical reactions. The aim of the present study was to comparatively analyze the effect of HNO and NO on several functional parameters of human platelets. For this purpose, sodium trioxodinitrate (Angeli’s salt, AS) and sodium nitroprusside (SNP) were used as HNO and NO releasers, respectively. Both AS and SNP significantly inhibited platelet aggregation and ATP release induced by different agonists and adrenaline. AS or SNP did not modify the expression of platelet glycoproteins (Ib, IIb-IIIa, Ia-IIa, IV), whereas they substantially decreased the levels of CD62P, CD63 and of PAC-1 (a platelet activated glycoprotein IIb/IIIa epitope) after the stimulation with ADP. AS and SNP significantly increased cGMP accumulation in a 1H-[1,2,4]oxadiazolo [4,3-a] quinoxalin-1-one (ODQ)-sensitive manner. However, while L-cysteine reduced the effect of AS, it increased the effect of SNP on this parameter. Accordingly, a differential effect of L-cysteine was observed on the antiaggregatory effect of both compounds. In summary, these results indicate that HNO is an effective inhibitor of human platelet aggregation.

Keywords

Nitroxyl - nitric oxide - platelet physiology

• References

• 1 Mellion BT, Ignarro LJ, Ohlstein EH. et al. Evidence for the inhibitory role of guanosine 3’, 5’-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators.. Blood 1981; 57: 946-55.
• 2 Radomski M-W, Palmer RMJ, Moncada S. An Larginine/ nitric oxide pathway present in human platelets regulates aggregation.. Proc Natl Acad Sci USA 1990; 87: 5193-7.
• 3 Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets.. Life Sci 1995; 57: 2049-55.
• 4 Moncada S, Radomski MW, Palmer RM. Endothelium- derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function.. Biochem Pharmacol 1988; 37: 2495-501.
• 5 Schmidt HH, Hofmann H, Schindler U. et al. No NO from NO synthase.. Proc Natl Acad Sci USA 1996; 93: 14492-7.
• 6 Adak S, Wang Q, Stuehr DJ. Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitricoxide synthase: Implications for mechanism.. J Biol Chem 2000; 275: 33554-61.
• 7 Xia Y, Zweier JL. Direct measurement of nitric oxide generation from nitric oxide synthase.. Proc Natl Acad Sci USA 1997; 94: 12705-10.
• 8 Tatarko M, Bumpus JA. Further studies on the inactivation by sodium azide of lignin peroxidase from Phanerochaete chrysosporium.. Arch Biochem Biophys 1997; 339: 200-9.
• 9 Arnelle DR, Stamler JS. NO+, NO, and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation.. Arch Biochem Biophys 1995; 318: 279-85.
• 10 Khan AU, Kovacic D, Kolbanovskiy A. et al. The decomposition of peroxynitrite to nitroxyl anion (NO-) and singlet oxygen in aqueous solution.. Proc Natl Acad Sci USA 2000; 97: 2984-9.
• 11 Sharpe MA, Cooper CE. Reactions of nitric oxide with mitochondrial cytochrome c: a novel mechanism for the formation of nitroxyl anion and peroxynitrite.. Biochem J 1998; 332: 9-19.
• 12 Miranda KM. The chemistry of nitroxyl (HNO) and implications in biology.. Coordination Chemistry Reviews 2005; 249: 433-55.
• 13 Ma XL, Gao F, Liu GL. et al. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury.. Proc Natl Acad Sci USA 1999; 96: 14617-22.
• 14 Paolocci N, Katori T, Champion HC. et al. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling.. Proc Natl Acad Sci USA 2003; 100: 5537-42.
• 15 Miranda KM, Nims RW, Thomas DD. et al. Comparison of the reactivity of nitric oxide and nitroxyl with heme proteins. A chemical discussion of the differential biological effects of these redox related products of NOS.. J Inorg Biochem 2003; 93: 52-60.
• 16 Wong PS, Hyun J, Fukuto JM. et al. Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry.. Biochemistry 1998; 37: 5362-71.
• 17 Feelisch M. Nitroxyl gets to the heart of the matter.. Proc Natl Acad Sci USA 2003; 100: 4978-80.
• 18 Mondoro TH, Ryan BB, Hrinczenko BW. et al. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease.. Br J Haematol 2001; 112: 1048-54.
• 19 Angeli A, Angelico F. Nuove richerche sopra l’acido nitroidrossilamminico.. Gazz Chim Ital 1903; 33: 245-52.
• 20 Bonner FT, Ravid B. Thermal decomposition of oxyhyponitrite (sodium trioxodinitrate II) in aqueous solution.. Inorg Chem 1975; 14: 558-63.
• 21 Miranda KM, Dutton AS, Ridnour LA. et al. Mechanism of aerobic decomposition of Angeli’s salt (sodium trioxodinitrate) at physiological pH.. J Am Chem Soc 2005; 127: 722-31.
• 22 Hughes MN, Cammack R. Synthesis, chemistry, and applications of nitroxyl ion releasers sodium trioxodinitrate or Angeli’s salt and Piloty’s acid.. Methods Enzymol 1999; 301: 279-87.
• 23 Hourdillé P, Hasitz M, Belloc F. et al. Immunocytochemical study of the binding of fibrinogen and thrombospondin to ADP- and thrombin –stimulated human platelets.. Blood 1985; 65: 912-20.
• 24 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal.. Nature 1962; 194: 927-9.
• 25 Feinman RD, Lubowsky J, Charo IF. et al. The lumiaggregometer: A new instrument for simultaneous measurement of secretion and aggregation.. J Lab Clin Med 1977; 90: 125-9.
• 26 Michelson A-D. Flow cytometry: A clinical test of platelet function.. Blood 1996; 87: 4925-36.
• 27 Shattil S-J, Cunningham M, Hoxie J-A. Detection of activated platelets in whole blood using activationdependent monoclonal antibodies and flow cytometry.. Blood 1987; 70: 307-15.
• 28 Chudzinski-Tavassi AM, Bermejo E, Rosenstein RE. et al. Nitridergic platelet pathway activation by hementerin, a metalloprotease from the leech Haementeria depressa.. Biol Chem 2003; 384: 1333-9.
• 29 Ellis A, Li CG, Rand MJ. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta.. Br J Pharmacol 2000; 129: 315-22.
• 30 Pino R, Feelisch M. Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine.. Biochem Biophys Res Commun 1994; 201: 54-62.
• 31 Vaananen AJ, Moed M, Tuominen RK. et al. Angeli’s salt induces neurotoxicity in dopaminergic neurons in vivo and in vitro.. Free Radic Res 2003; 37: 381-9.
• 32 Miranda KM, Paolocci N, Katori T. el al. A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system.. Proc Natl Acad Sci USA 2003; 100: 9196-201.
• 33 Zamora R, Grzesiok A, Weber H. et al. Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty’s acid: a comparison with Angeli’s salt.. Biochem J 1995; 312: 333-9.
• 34 Dierks EA, Burstyn JN. Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase.. Biochem Pharmacol 1996; 51: 1593-600.
• 35 Fukuto JM, Chiang K, Hszieh R. et al. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endotheliumderived relaxing factor.. J Pharmacol Exp Ther 1992; 263: 546-51.
• 36 Vanuffelen BE, Van Der Zee J, De Koster BM. et al. Intracellular but not extracellular conversion of nitroxyl anion into nitric oxide leads to stimulation of human neutrophil migration.. Biochem J 1998; 330: 719-22.
• 37 Costa G, Labadia A, Triguero D. et al. Nitrergic relaxation in urethral smooth muscle: involvement of potassium channels and alternative redox forms of NO.. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 516-23.
• 38 Wanstall JC, Jeffery TK, Gambino A. et al. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion.. Br J Pharmacol 2001; 134: 463-72.
• 39 Yan B, Smith JW. A redox site involved in integrin activation.. J Biol Chem 2000; 275: 39964-72.
• 40 Keh D, Thieme A, Kurer I. et al. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine.. Blood Coagul Fibrinolysis 2003; 14: 327-34.
• 41 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.. Mol Pharmacol 1990; 37: 671-81
• 42 Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.. Physiol Rev 1995; 75: 725-48.
• 43 Li Z, Xi X, Gu M. et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation.. Cell 2003; 112: 77-86.
• 44 Jensen BO, Selheim F, Doskeland SO. et al. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide.. Blood 2004; 104: 2775-82.
• 45 Li Z, Ajdic J, Eigenthaler M. et al. A predominant role for cAMP-dependent protein kinase in the cGMPinduced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans.. Blood 2003; 101: 4423-9.
• 46 Jang EK, Azzam JE, Dickinson NT. et al. Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside.. Br J Haematol. 2002; 117: 664-75.
• 47 Li Z, Zhang G, Marjanovic JA. et al. A platelet secretion pathway mediated by cGMP-dependent protein kinase.. J Biol Chem 2004; 279: 42469-75.